Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Tuberous Sclerosis 4Seizures 3Lennox Gastaut Syndrome 3Epilepsies, Myoclonic 3Anxiety Disorders 2Tuberous Sclerosis 2 1Tuberous Sclerosis 1 1Spasms, Infantile 1Prostatic Neoplasms 1Parasomnias 1Pain 1Neoplasms 1Nausea 1Marijuana Abuse 1Liver Cirrhosis 1Glioblastoma 1Epilepsy 1Colorectal Neoplasms 1Colonic Neoplasms 1Chemotherapy-Induced Peripheral Neuropathy 1Carcinoma, Intraductal, Noninfiltrating 1Cancer Pain 1Breast Neoplasms 1Breast Carcinoma In Situ 1Behavior 1

Interventions

Temozolomide 101Radiotherapy 50Magnetic Resonance Spectroscopy 38Radiation 28Specimen Handling 25pembrolizumab 23Bevacizumab 23Lomustine 16Nivolumab 14Surgical Procedures, Operative 11atezolizumab 8Cyclophosphamide 8Biopsy 8abemaciclib 7Ipilimumab 7Carboplatin 7fludarabine 6Radiotherapy, Intensity-Modulated 6Aminolevulinic Acid 6olaparib 5Metformin 5Drug Therapy 5Diet, Ketogenic 5Dianhydrogalactitol 5regorafenib 4poly ICLC 4cemiplimab 4Radiosurgery 4Photons 4Leukapheresis 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioblastoma × Cannabidiol × 1 year × Clear all
NCT05753007 2026-03-16

A Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patients

Mclean Hospital

Phase 2 Terminated
2 enrolled 13 charts
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡